Net Savings Link Inc (OTCMKTS:NSAV) announced recently that its Strategic Research Institute (VSRI) based in Shanghai is developing the Blockchain Technology into its systems to improve the quality of its clinical research. With Blockchain, the company believes it will have a competitive advantage over its rivals in the industry.
VSRI focuses on designing clinical trials across the globe. The company has partnered with Pfizer, Bristol-Myers Squibb, and other giant pharmaceutical companies. In late last year, the company signed an agreement with Eli Lilly and Company to provide Eli Lilly with an evaluation of Cardio Vascular Disease (CVD) among the newly diagnosed patients with diabetes in China. Currently, over 11% of the population in China suffers from diabetes and other metabolic conditions with more than 200 million people suffer from CVD and related cases, a world’s leading cause of death.
The company also announced that it has contracted Medtronic PLC to team up in its Heart Rescue Project that is headed by VSRI and Shanghai Jiao Tong University (SITU) School of Medicine. The project intends to enhance the access to quality treatment for acute CVD care in China.
According to James Tilton, President of Net Savings Link, the Blockchain Technology will put the company at the forefront of the innovation and there are numerous benefits accrued when incorporating Blockchain in the clinical research and clinical trials.
The company has a fully integrated technology that offers numerous technological and software solutions in the medical field. Furthermore, the firm is planning to expand and integrate its services, which include software solutions, e-commerce, financial services, patents and trademarks advisory services and information technology to serve a wider market.
In addition, Net Savings Link announced recently that it has packaged the first Hemp beer in China that corresponded with the beginning of China’s Lantern Festivals. The launch was a joint venture between the company and the Blue Candy Brewery, one of its partners based in China.